论文部分内容阅读
目的:观察杏贝止咳祛痰口服液辅助治疗小儿支气管肺炎的疗效。方法:90例支气管肺炎住院患儿,随机分成两组,治疗组47例给予支气管肺炎常规治疗(依病原菌选择给予头孢或阿奇霉素治疗,病毒性肺炎不给予抗生素,合并喘息患儿给予复方异丙托溴胺雾化治疗)的基础上,加用杏贝止咳祛痰口服液口服。对照组43例仅给予常规治疗。7 d为1个疗程,观察患儿体温、咳嗽、肺部体征变化、疾病转归及住院天数。结果:治疗组患儿咳嗽明显好转(咳嗽频率减低>50%)时间及住院天数均短于对照组,患儿体温降至正常的时间及肺部体征消失的时间均短于对照组(P>0.05)。治疗组患儿总有效率高于对照组(P<0.05),未愈率低于对照组。治疗组不良反应发生率低于对照组(P>0.05)。结论:杏贝止咳祛痰口服液辅助治疗小儿支气管肺炎可以缩短患儿症状和肺部体征恢复时间及住院天数,提高治疗的有效性,未见明显不良反应。
Objective: To observe the curative effect of apricot shell cough and expectorant phlegm adjuvant therapy on bronchial pneumonia in children. Methods: Ninety children hospitalized with bronchopneumonia were randomly divided into two groups. The treatment group was given routine treatment of bronchial pneumonia (according to the pathogen selection of cephalosporins or azithromycin treatment, viral pneumonia was not given antibiotics, combined with asthma in children given compound ipratropium Bromine amine atomization treatment) based on the addition of apricot shell cough expectorant oral solution oral. The control group, 43 cases were given only conventional treatment. 7 d for a course of treatment, observed in children with body temperature, cough, lung signs, disease and hospitalization days. Results: The cough was significantly improved (cough frequency reduced> 50%) in the treatment group and the days in the hospitalization were shorter than those in the control group. The time when the body temperature dropped to normal and the disappearance of the lung sign were shorter than those in the control group (P> 0.05). The total effective rate in the treatment group was higher than that in the control group (P <0.05), and the unharmed rate was lower than that in the control group. The incidence of adverse reactions in the treatment group was lower than that in the control group (P> 0.05). Conclusion: Apricot Bay cough and expectorant phlegm oral adjuvant treatment of children with bronchial pneumonia can shorten the symptoms of children and lung signs recovery time and hospital stay, improve the effectiveness of treatment, no obvious adverse reactions.